XERS (Xeris Biopharma Holdings) Total Liabilities: $379.0 Mil (As of Mar. 2026)

What is Xeris Biopharma Holdings Total Liabilities?

Xeris Biopharma Holdings XERS -3.30% 71 Total Liabilities is $379.0 Mil as of Mar. 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Xeris Biopharma Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $379.0 Mil.

Xeris Biopharma Holdings's quarterly Total Liabilities declined from Sep. 2025 ($371.05 Mil) to Dec. 2025 ($369.84 Mil) but then increased from Dec. 2025 ($369.84 Mil) to Mar. 2026 ($379.00 Mil).

Xeris Biopharma Holdings's annual Total Liabilities increased from Dec. 2023 ($329.38 Mil) to Dec. 2024 ($352.68 Mil) and increased from Dec. 2024 ($352.68 Mil) to Dec. 2025 ($369.84 Mil).

Xeris Biopharma Holdings Total Liabilities Related Terms

Xeris Biopharma Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Total Liabilities Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

209.13

299.34

329.38

352.68

369.84

Xeris Biopharma Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															350.58	353.99	371.05	369.84	379.00

71GF Score

Xeris Biopharma Holdings Inc XERS

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xeris Biopharma Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xeris Biopharma Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	109.574	+	(251.866	+	8.398
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	369.8

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	383.527	-	13.689
	=	369.8

Xeris Biopharma Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	118.593	+	(252.282	+	8.127
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	379.0

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	392.013	-	13.011
	=	379.0

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $379.0 Mil mean?

Xeris Biopharma Holdings (XERS) has a Total Liabilities of $379.0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xeris Biopharma Holdings and its competitors.

Is Xeris Biopharma Holdings' Total Liabilities too high?

Xeris Biopharma Holdings' current Total Liabilities is $379.0 Mil. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Xeris Biopharma Holdings' Total Liabilities compare to PAHC and PRGO?

Xeris Biopharma Holdings' Total Liabilities of $379.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Total Liabilities is $379.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xeris Biopharma Holdings stock overvalued right now?

Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Total Liabilities is $379.0 Mil. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Total Liabilities is $379.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

Total Liabilities: $379.0 Mil
GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies PAHC PRGO ALVO COLL HROW BIOA PCRX ETON AMPH TRLV XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 0A8E:UK 2B30:Germany

Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

71GF Score

Get the complete analysis for XERS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.35

Price

$5.19

GF Value

View XERS Analysis

See Total Liabilities data for all stocks →